2 FTSE 100 shares with new catalysts for growth

Both these FTSE 100 shares are backed by businesses with exciting new plans to refocus and grow operations in the coming years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A pastel colored growing graph with rising rocket.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I don’t have any cash to invest right now. But when it comes to FTSE 100 shares, I’m keen on Smith & Nephew (LSE: SN), the medical technology company. It provides products and services in the areas of orthopaedics, advanced wound management, sports medicine, and ear, nose & throat (ENT). 

Targeting better execution

In November 2022, the company released a third-quarter trading report showing steady progress. And that came after the directors announced a 12-point plan in July “to drive better execution at pace”.

I’m optimistic the new focus can drive better financial outcomes over the next few years. And City analysts have pencilled in higher earnings ahead, close to pre-pandemic levels. Although there’s no certainty the company will make its estimates.

Nevertheless, with the share price in the ballpark of 1,200p, the valuation looks fair to me. The forward-looking price-to-earnings ratio is just below 17. And the share price is around 37% below its 2019 peak.

I see Smith & Nephew as a high-quality enterprise with some defensive attractions. Nevertheless, the pandemic caused the business some problems. However, the firm has carried a high-looking valuation for as long as I can remember. So today’s level looks reasonable by comparison.

Over the past year, the stock has more or less returned to where it started after dipping lower. And I’m hopeful that operational momentum can keep the share price moving higher in the coming months.

We’ll find out more from the company with the full-year results report due on 21 February. But in the meantime, I also like the look of Croda International (LSE: CRDA).

Refocusing the business

It’s a global speciality chemical company creating ingredients and technologies for products used by industry and consumers worldwide. And the ingredients often make up only a small percentage of the finished product. But “it is that unique percentage that makes the difference by delivering unique performance benefits”, it says.

The business is another quality operator with a high valuation to match. But what I like about the stock now is the directors’ new determination to refocus the business. Over the past 18 months or so, Croda has “accelerated” key elements of its strategy to transition to a dedicated consumer care and life sciences company. 

And I reckon a narrower focus and concentrated effort is almost always a positive thing in business. My hope is the firm’s new, clearer direction will lead to improving profits in the years ahead.

Strong profits and cash flow

Meanwhile, the share price is around 30% below its December 2021 peak because of the general weakness in the markets. But Croda’s profits and cash flow have held up well during the period.

I see the current share price in the region of 7,100p as an opportunity for me. Although there’s no guarantee earnings will improve in the future. And I could even lose money on the shares if the company’s plans don’t work out as expected.

Nevertheless, I’d be tempted to buy some of the shares now to hold for the long term. However, there is valuation risk here. The forward-looking earnings multiple for 2023 is running at just below 29. And that’s despite the recent falls on the share price chart. 

We’ll find out more about operational progress with the full-year results report due on 28 February.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended Croda International Plc and Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »